(Total Views: 438)
Posted On: 04/15/2020 8:50:50 AM
Post# of 72440
If the following events become reality in regards to Brilacidin testing currently underway for CV19 vaccine adjunct/treatment for respiratory problems using an IV and they also test the IBD pill for treatment of those patients w/ CV19 that have IBD problems, where would that leave IPIX and Brilacidin in regards to clinical trials standing for specific indications w/ the FDA? In all cases it would be assumed that B showed extremely strong safety indications with little to no side effects on a great number of patients:
1 B proves to stop/greatly mitigate the virus / bacteria in the lungs that lead to CV deadly issues and also shows evidence of stopping COPD/Asthma in those same patients.
2 The IBD pill shows evidence of relieving IBD issues such as Colitis and Crohn's in CV patients in addition to stopping the CV virus in the lower GI tract.
3 B proves to work efficiently as an antibiotic in CV patients.
Would anybody think this enormous amount of actual data on live patients would move all the indications to at least P3 or possibly beyond for Brilicadin IBD, Respiratory, and ABSSSI?
What would that do for the value of the entire Brilacidin platform as IMO these indications would allow any company to immediately become a BP based on revenue producing stream?
Though this sounds like a polyanna dream, I think most of us would say such findings are highly likely, or at least possible.
Exciting times, B could be the start of new visions for medicine in advancing new drugs based on AI computational findings as opposed to the old fashioned decade long process to get new drugs commercialized. Sure hope so.
1 B proves to stop/greatly mitigate the virus / bacteria in the lungs that lead to CV deadly issues and also shows evidence of stopping COPD/Asthma in those same patients.
2 The IBD pill shows evidence of relieving IBD issues such as Colitis and Crohn's in CV patients in addition to stopping the CV virus in the lower GI tract.
3 B proves to work efficiently as an antibiotic in CV patients.
Would anybody think this enormous amount of actual data on live patients would move all the indications to at least P3 or possibly beyond for Brilicadin IBD, Respiratory, and ABSSSI?
What would that do for the value of the entire Brilacidin platform as IMO these indications would allow any company to immediately become a BP based on revenue producing stream?
Though this sounds like a polyanna dream, I think most of us would say such findings are highly likely, or at least possible.
Exciting times, B could be the start of new visions for medicine in advancing new drugs based on AI computational findings as opposed to the old fashioned decade long process to get new drugs commercialized. Sure hope so.
(9)
(0)Scroll down for more posts ▼
